Topic
GSK
11 stories related to this topic, newest first.
citizen.co.zaworld22 days ago
Shingrix shingles vaccine registered in South Africa but public-sector rollout still undecided
AllAfrica reported that GSK's Shingrix received SAHPRA registration in June 2026 and will launch at R2,783 per dose by the end of the month. Initial availability is limited to the private sector while public sector review remains pending.
benzinga.comworld39 days ago
GSK to Reverse Oncology Exit With Largest Acquisition in Eight Years
The company is buying a cancer-focused business in its biggest deal since 2018, reversing an earlier decision to exit the field.
MA
benzinga.comscience39 days ago
GSK Acquires Rights to Three Experimental Lung Cancer Drug Candidates, Two Under FDA Review
The deal will transfer ownership of three experimental treatments, two of which are already under FDA review for approval this year.
The Independentscience50 days ago
GSK Hepatitis B Drug Shows Functional Cure in 20 Percent of Trial Patients
Two international studies found that bepirovirsen produced sustained viral suppression in roughly one-fifth of participants after treatment ended. The drug is under FDA fast-track review with a decision expected in October.
Statscience50 days ago
GSK Drug Achieves Functional Cure in 19-20% of Hepatitis B Patients
Two Phase 3 trials showed GSK's bepirovirsen produced functional cures in nearly one-fifth of chronic hepatitis B patients. Current nucleoside analogue treatments reach functional cures in only 1-3% of cases. The company has submitted the drug for regulatory approval.
uctoday.comworld71 days ago
Moderna's mRESVIA Faces Challenges in RSV Vaccine Market
A Seeking Alpha analysis reported that Moderna's mRESVIA RSV vaccine has struggled to gain market share against established competitors in 2026. Pfizer and GSK secured early advantages through supply chain and contract arrangements following their first-to-market launches.
SE
Substrate placeholder — needs reviewscience95 days ago
GSK Presents Early-Stage Data on Experimental Cancer Drug and Plans Five Phase 3 Trials
GSK presented data from an early-stage clinical trial of an experimental cancer drug over the weekend. The company stated that the results support advancing the drug to five Phase 3 trials this year. This development follows initial testing to evaluate the drug's safety and preli…
ST
Substrate placeholder — needs reviewworld96 days ago
GSK Plans Five Simultaneous Late-Stage Trials for Potential Blockbuster Cancer Drug
GSK Plc announced plans for five concurrent phase 3 trials of a targeted cancer therapy following promising early data. The initiative aims to advance the drug toward potential blockbuster status. The new CEO is leading efforts to revitalize the company's approach to innovation.
BU
RE
medpagetoday.comscience98 days ago
Recent Developments in CAR-T Therapy for Autoimmunity and GSK's Discontinuation of Leucovorin
Researchers are exploring CAR-T cell therapy's potential in treating autoimmune diseases beyond cancer. GlaxoSmithKline announced it will discontinue leucovorin, a drug used in chemotherapy support. These updates highlight ongoing advancements and changes in the biotechnology sec…
ST
Substrate placeholder — needs reviewscience98 days ago
FDA Withdraws Approval of GSK Drug; GLP-1 Generics Enter India Market; Estrogen Patches Face Shortage
The U.S. Food and Drug Administration withdrew approval for a GlaxoSmithKline drug previously promoted by the Trump administration for autism treatment. In India, generic versions of GLP-1 drugs are entering the obesity treatment market. A shortage of estrogen patches used for me…
ST
Substrate placeholder — needs reviewscience98 days ago
FDA Withdraws Approval for GSK's Leucovorin in Treating Cerebral Folate Deficiency
The U.S. Food and Drug Administration is withdrawing approval for GlaxoSmithKline's leucovorin as a treatment for cerebral folate deficiency, a rare brain disorder. GSK stated that the withdrawal was anticipated as part of the original approval plan. The disorder involves symptom…
ST